Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7444973 in MAGE-A4-positive Solid Tumors
NCT05129280Phase 1Terminated
- Sponsor
- Roche
- Start
- Jan 2022
- Primary completion
- Jul 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of RO7444973 in solid tumor, sponsored by Roche. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events up to 15 months and Number of Participants With Dose-limiting Toxicities up to 28 days. Started Jan 2022; status: terminated.
02
Drugs
RO7444973
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05129280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05129280.